We report here the first case report of bone marrow transplantation ( 
fusions of red cells and platelets within a month. It had not yet been established that immunosuppressive drugs such as antithymocyte globulin (ATG) and cyclosporine were effective in restoring hematopoietic function in some patients with aplastic anemia. He subsequently underwent a non T cell-depleted BMT (total 2.5 ϫ 10 10 nucleated cells) with donor cells from his 15-year-old HLA-identical sibling following preparation with cyclophosphamide (120 mg/kg) and total lymphoid irradiation (705 cGy) in February 1990. A bone marrow aspirate performed a month post BMT revealed satisfactory donor cell engraftment. The HLA-matched sibling donor was a healthy HTLV-I carrier, and the patient and his family were therefore fully informed regarding the risk of BMT-related HTLV-I transmission and the development of ATL or HAM/TSP. After a year, the Japan Marrow Donor Program (JMDP) was established.
Serum anti-HTLV-I antibodies were detected by the gelatin particle aggulutination test (PA) (Serodia-ATLA, Fuji Lebio, Tokyo, Japan) and Western blot analysis (WB) using MT-2 2 cells as a source of antigen. The results are shown in Figures 1 and 2 . Anti-HTLV-I was positive by PA at a titer of 1:256 in the donor serum, and this was confirmed by WB. Antibodies to core proteins (p19 and p24) were also detected in the serum (Figure 1 ). Anti-HTLV-I was not detected by PA or WB in the recipient's serum 9 days prior to BMT, but was detected in the recipient's serum 12 days following BMT with a titer of 1:32 by PA. Serial anti-HTLV-I analysis was subsequently performed on the recipient. The highest serum titer of anti-HTLV-I (1:4096) was seen at 1030 days. In addition, HTLV-I-specific IgG against core proteins (anti-p19 and anti-p24) and HTLV-I-specific IgM against gag and env proteins (anti-p19, anti-p24 and anti-gp46) were detected by WB during seroconversion, as seen in Figures 1 and 2 . However, we were unable to detect IgG antibodies to gp46 before 482 days post BMT (Figure 1 ), although IgM antibodies to gp46 were detected at 151 days ( Figure 2 ). The intensity of the anti-p19 and anti-p24 WB bands increased over time following initial seroconversion, accompanied by increased antibody titers by PA (Figure 1 ). These antibodies were persistently positive for more than 4 years and we were able to detect seropositivity by PA 4. years following BMT. We have not examined these antibodies since 1995. However, CD4-positive lymphocytes have not been increased, and the 'flower' cells characteristic of typical ATL have not been observed in the recipient, who remains in remission without developing ATL or HAM/TSP.
Discussion
It has previously been reported that the incidence of anti-HTLV-I seroconversion following blood transfusion (cellular components) reaches 63%. 1 The median time to seroconversion following transmission was 51 days (36 to 72 days), with seropositivity defined by the presence of anti-p24 and anti-gp46 and/or anti-p21 on recombinant WB. 3 Anti-p19 and anti-p24 were detectable within 30 to 60 days. 4 Kamihira et al 4 reported HTLV-I-specific IgM antibodies appearing as early as 2 weeks following blood transfusions, with maximum positivity after 8 weeks. In contrast, we report that IgM antibodies were detected 151 days following BMT. IgG against core protein appeared earlier than IgM antibodies to gag and env proteins during seroconversion. These data differ from those of blood transfusion-related seroconversion, and the discrepancy between these data and those of blood transfusion-related seroconversion remains to be clarified. This phenomenon may be due to engraftment of donor anti-HTLV-I producing cells since anti-HTLV-I was positive by PA and WB at the earliest time point (12 days) post BMT. The only evidence supporting the acquisition of a new infection post BMT is the fact that recipient was seronegative before BMT, but this is based on a single seronegative serum specimen. This specimen was obtained after diagnosis and treatment for SAA. This treatment included methylprednisolone which might have predisposed to a false negative HTLV-I serology. There is the concern that the sibling relationship would predispose the recipient to prior HTLV-I infection and that the serology in a sick person before BMT represented by a false negative result. Therefore, there is a possibility that the pre-BMT serology is a false negative result and that the presence of IgM antibody post BMT is not incontrovertible evidence for recent infection. Some reports of allogeneic BMT in ATL suggest possible eradication of the malignant clone. However, there have been few reports of HTLV-I infection after BMT. Recently Kawa et al 5 reported complete eradication of HTLV-I by allogeneic BMT from an HLA-identical, HTLV-I negative sibling donor. In one report, however, HTLV-I antibody still persisted 37 months after BMT. 6 In addition, Ljungman et al 7 reported an infection with HTLV-I in donor lymphocytes after BMT for an HTLV-I-positive ATL patient.
Two cases of ATL following transfusion-acquired HTLV-I infection in patients with prior diagnosis of Hodgkin's disease or aplastic anemia have been reported at 6 months and 11 years after blood transfusion.
8 Transfusionassociated HAM/TSP have occurred within several weeks to 3 years following transfusion. 9 The clinical prognosis of this patient is now under observation.
phocytes with human T lymphotropic virus type I (HTLV-I) following allogeneic bone marrow transplantation for HTLV-I positive adult T-cell leukaemia. 
